Exagen Dirección
Dirección controles de criterios 3/4
Actualmente no disponemos de información suficiente sobre el CEO.
Información clave
John Aballi
Chief Executive Officer (CEO)
US$932.0k
Compensación total
Porcentaje del salario del CEO | 56.3% |
Permanencia del CEO | 2yrs |
Participación del CEO | 1.2% |
Permanencia media de la dirección | 2yrs |
Promedio de permanencia en la Junta Directiva | 4.8yrs |
Actualizaciones recientes de la dirección
Recent updates
Improved Revenues Required Before Exagen Inc. (NASDAQ:XGN) Stock's 40% Jump Looks Justified
Sep 06Analyst Estimates: Here's What Brokers Think Of Exagen Inc. (NASDAQ:XGN) After Its Second-Quarter Report
Aug 07Insufficient Growth At Exagen Inc. (NASDAQ:XGN) Hampers Share Price
Jul 13Is Exagen (NASDAQ:XGN) Using Debt In A Risky Way?
May 21Why Investors Shouldn't Be Surprised By Exagen Inc.'s (NASDAQ:XGN) 31% Share Price Plunge
Mar 26Analysts Have Made A Financial Statement On Exagen Inc.'s (NASDAQ:XGN) Annual Report
Mar 22Exagen Inc.'s (NASDAQ:XGN) Business And Shares Still Trailing The Industry
Jul 21Exagen appoints John Aballi as CEO
Oct 17Analysts Just Slashed Their Exagen Inc. (NASDAQ:XGN) EPS Numbers
Aug 10Exagen (NASDAQ:XGN) Has Debt But No Earnings; Should You Worry?
Jul 26Is Exagen (NASDAQ:XGN) Weighed On By Its Debt Load?
Apr 05Does Exagen (NASDAQ:XGN) Have A Healthy Balance Sheet?
Dec 03Does Exagen (NASDAQ:XGN) Have A Healthy Balance Sheet?
Aug 06Exagen Inc.'s (NASDAQ:XGN) Intrinsic Value Is Potentially 62% Above Its Share Price
Apr 07Is Exagen (NASDAQ:XGN) Using Too Much Debt?
Mar 03Exagen issues preliminary testing revenue ahead of ICT chat
Jan 11Would Shareholders Who Purchased Exagen's (NASDAQ:XGN) Stock Year Be Happy With The Share price Today?
Jan 05Exagen (XGN) Investor Presentation - Slideshow
Nov 20Análisis de compensación del CEO
Fecha | Compensación total | Salario | Ingresos de la empresa |
---|---|---|---|
Jun 30 2024 | n/a | n/a | -US$17m |
Mar 31 2024 | n/a | n/a | -US$19m |
Dec 31 2023 | US$932k | US$525k | -US$24m |
Sep 30 2023 | n/a | n/a | -US$32m |
Jun 30 2023 | n/a | n/a | -US$35m |
Mar 31 2023 | n/a | n/a | -US$45m |
Dec 31 2022 | US$1m | US$111k | -US$47m |
Compensación vs. Mercado: La compensación total de John($USD931.95K) está por encima de la media de empresas de tamaño similar en el mercado US ($USD673.68K).
Compensación vs. Ingresos: La compensación de John ha sido consistente con los resultados de la empresa en el último año.
CEO
John Aballi (39 yo)
2yrs
Permanencia
US$931,950
Compensación
Mr. John Aballi serves as President, Chief Executive Officer and Director at Exagen Inc. since October 17, 2022 and served as its Interim Chief Financial Officer since August 2024 until August 31, 2024. Mo...
Equipo directivo
Nombre | Posición | Permanencia | Compensación | Propiedad |
---|---|---|---|---|
Executive Chairman of the Board of Directors | 5.3yrs | US$132.81k | 0% $ 0 | |
CEO, President & Director | 2yrs | US$931.95k | 1.17% $ 602.9k | |
Corporate Secretary | 7.1yrs | US$915.09k | 0.30% $ 155.8k | |
Investors Relations Officer | no data | sin datos | sin datos | |
Chief Innovation Officer & Member of Rheumatoid Arthritis Scientific Advisory Board | 2yrs | sin datos | sin datos | |
Chief Medical Officer | 1.4yrs | sin datos | sin datos |
2.0yrs
Permanencia media
57yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de XGN se considera experimentado (2 años antigüedad media).
Miembros de la Junta
Nombre | Posición | Permanencia | Compensación | Propiedad |
---|---|---|---|---|
Executive Chairman of the Board of Directors | 5.3yrs | US$132.81k | 0% $ 0 | |
CEO, President & Director | 2yrs | US$931.95k | 1.17% $ 602.9k | |
Chief Innovation Officer & Member of Rheumatoid Arthritis Scientific Advisory Board | 4.8yrs | sin datos | sin datos | |
Member of Breast Cancer Advisory Board | no data | sin datos | sin datos | |
Member of Breast Cancer Advisory Board | no data | sin datos | sin datos | |
Independent Director | 5.3yrs | US$33.75k | sin datos | |
Member of Breast Cancer Advisory Board | no data | sin datos | sin datos | |
Member of Breast Cancer Advisory Board | no data | sin datos | sin datos | |
Member of Breast Cancer Advisory Board | no data | sin datos | sin datos | |
Member of Breast Cancer Advisory Board | no data | sin datos | sin datos | |
Chairman of Scientific Advisory Board | 4.8yrs | US$130.00k | sin datos | |
Independent Director | 3.3yrs | US$82.70k | 0% $ 0 |
4.8yrs
Permanencia media
63.5yo
Promedio de edad
Junta con experiencia: La junta directiva de XGN se considera experimentada (4.5 años de antigüedad promedio).